2321-PUB: Improved Glycemic Control among Patients Newly Prescribed IDegLira across Various Background Therapies in U.S. Real-World Practice

IDegLira is a fixed-ratio combination of degludec and liraglutide indicated for the treatment of type 2 diabetes (T2D). This is the first real world study describing change in glycated hemoglobin (HbA 1c ) among U.S. patients initiating IDegLira. The primary objective was to observe the effect in metabolic control of initiating IDegLira in adult T2D patients previously on basal insulin (Basal), glucagon-like peptide-1 receptor agonist as only injectable (GLP-1), and no injectable therapy (N-INJ) between March 2017 and June 2018 (index date). Patients with HbA 1c data 6 months prior to and 6m post index date were included from the Practice Fusion Electronic Health Record database. Of the 1,384 IDegLira patients, 206 patients had baseline, and follow-up HbA 1c (180 ± 45 days) data. Changes in clinical outcomes were evaluated by paired t-test. Overall there was significant change in HbA 1c of -0.9% (p 1c reduction in all three background therapy groups, ranging from -0.7 in the Basal to -1.0 in N-INJ (p 1c across different background therapies with minimal impact on weight. Disclosure L.E. Egede: Consultant; Self; Novo Nordisk Inc. Research Support; Self; National Institute of Diabetes and Digestive and Kidney Diseases. A. Bogdanov: None. L. Fischer: None. J. da Rocha Fernandes: Employee; Self; Novo Nordisk A/S. L. Kallenbach: Employee; Self; Veradigm. Funding Novo Nordisk